|
SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO
|
0.100 |
SusceptibilityMutation
|
phenotype |
CLINVAR |
|
|
|
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
|
19217207 |
2009 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TRAP1 is a mitochondrial antiapoptotic protein up-regulated in several human malignancies.
|
23735188 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
TRAP1 controls NSCLC proliferation, apoptosis, and mitochondrial function, and its status has prognostic potential in NSCLC.
|
24567527 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TRAP1 was overexpressed in ESCC, particularly in poorly differentiated tumors.
|
24754231 |
2014 |
|
Colorectal Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: relevance in human colorectal tumors.
|
24962791 |
2014 |
|
Metastatic Prostate Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAP1/Hsp75 (tumor necrosis factor receptor-associated protein 1), a paralogue of the Hsp90 family, has been recently described as a molecular marker and novel therapeutic target in local and metastatic prostate cancer.
|
25189320 |
2015 |
|
Metastasis from malignant tumor of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAP1/Hsp75 (tumor necrosis factor receptor-associated protein 1), a paralogue of the Hsp90 family, has been recently described as a molecular marker and novel therapeutic target in local and metastatic prostate cancer.
|
25189320 |
2015 |
|
Colorectal Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
|
25239454 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRAP1 knockdown downregulates mitochondrial aerobic respiratory, sensitizes cells to lethal stimuli, and inhibited tumor growth in MDA-MB-231 and MCF-7 breast cancer cells in vivo.
|
26517089 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRAP1 role in thyroid carcinoma (TC), still unaddressed at present, was investigated by analyzing its expression in a cohort of 86 human TCs and evaluating its involvement in cancer cell survival and proliferation in vitro Indeed, TRAP1 levels progressively increased from normal peritumoral thyroid gland, to papillary TCs (PTCs), follicular variants of PTCs (FV-PTCs) and poorly differentiated TCs (PDTCs).
|
27422900 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
TRAP1 role in thyroid carcinoma (TC), still unaddressed at present, was investigated by analyzing its expression in a cohort of 86 human TCs and evaluating its involvement in cancer cell survival and proliferation in vitro Indeed, TRAP1 levels progressively increased from normal peritumoral thyroid gland, to papillary TCs (PTCs), follicular variants of PTCs (FV-PTCs) and poorly differentiated TCs (PDTCs).
|
27422900 |
2016 |
|
Tumor Cell Invasion
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
|
27977010 |
2016 |
|
Metastatic Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma.
|
28177905 |
2017 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
TRAP1 is upregulated at the transition between low- and high-grade adenomas, in in situ carcinomas and in about 60% of human colorectal carcinomas, being downregulated only in a small cohort of tumors.
|
28177905 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TRAP1 is upregulated at the transition between low- and high-grade adenomas, in in situ carcinomas and in about 60% of human colorectal carcinomas, being downregulated only in a small cohort of tumors.
|
28177905 |
2017 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
TRAP1 regulates autophagy in lung cancer cells.
|
29383696 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAP1 regulates autophagy in lung cancer cells.
|
29383696 |
2018 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAP1 regulates autophagy in lung cancer cells.
|
29383696 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor.
|
29621137 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
TRAP1 Regulation of Cancer Metabolism: Dual Role as Oncogene or Tumor Suppressor.
|
29621137 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A case control study was performed to explore the association between TRAP1 gene polymorphisms and susceptibility to SLE, then the SLE patients included in the case control study were followed to investigate the relationship between TRAP1 gene polymorphisms and efficacy of GCs.
|
29859285 |
2018 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Malignant neoplasm of stomach
|
0.300 |
Biomarker
|
disease |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
|
21364753 |
2011 |